Endometrial Cancer Clinical Trials in Buffalo, New York

9 studies are recruiting for endometrial cancer in Buffalo, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Roswell Park Cancer Institute IDS, Buffalo, New York

   Locations

   90 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

2. Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

   This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / N…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Roswell Park Cancer Institute, Buffalo, New York

   Locations

   121 in total

   Run by

   Canadian Cancer Trials Group

   See if you can join NCT05640999 on ClinicalTrials.gov

3. Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

   The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park Cancer Institute, Buffalo, New York

   Locations

   53 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT03564340 on ClinicalTrials.gov

4. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

   This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park Comprehensive Cancer Center, Buffalo, New York

   Locations

   14 in total

   Run by

   NextCure, Inc.

   See if you can join NCT06774963 on ClinicalTrials.gov

5. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park Cancer Institute, Buffalo, New York

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

6. Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

   HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park Comprehensive Care Center, Buffalo, New York

   Locations

   12 in total

   Run by

   Whitehawk Therapeutics, Inc.

   See if you can join NCT07444814 on ClinicalTrials.gov

7. A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

   This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Roswell Park, Buffalo, New York

   Locations

   21 in total

   Run by

   Alliance Foundation Trials, LLC.

   See if you can join NCT04486352 on ClinicalTrials.gov

8. A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

   The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.

   Stage

   Phase 2

   Ages

   18 to 70

   Site

   Roswell Park Cancer Institute, Buffalo, New York

   Locations

   12 in total

   Run by

   Iovance Biotherapeutics, Inc.

   See if you can join NCT06481592 on ClinicalTrials.gov

9. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Buffalo, New York

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov